VB7-756

VB7-756 is a **targeted protein therapeutic (TPT)** composed of a de-immunized form of bouganin (deBouganin), a potent, plant-derived, type I ribosome-inactivating protein, genetically linked through a furin protease-sensitive linker to the anti-HER2 C6.5 diabody. The optimal format involves deBouganin covalently attached to the N-terminus of the VH-VL diabody. VB7-756 targets HER2-positive cancer cells and shows potent cytotoxicity, particularly in breast cancer cell lines with high HER2 expression, outperforming reference antibody-drug conjugates (T-DM1 and T-MMAE) and overcoming resistance mechanisms to tubulin inhibitors by eliminating cells surviving these treatments. Its mechanism relies on deBouganin's ribosome-inactivation, leading to cell death even in cancer stem-like cells and tumor-initiating subpopulations[1][4].

Other names

VB7-756VB-7-756VB 7-756VB7756VB-7756VB 7756